Back to top

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Relmada Therapeutics, with a price target of $19.00. According...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Relmada Therapeutics, Inc. (RLMD)